Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | completed | Phase 1 | 6 | Julio Barredo, MDOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | completed | Phase 1 | 39 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03723681 | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT02109744 | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients(AML) | completed | Phase 1 / Phase 2 | 27 | University of RochesterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT01093573 | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 34 | Brenda Cooper, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03848754 | Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 14 | Medical College of WisconsinOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT03483324 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | completed | Phase 1 | 10 | Angiocrine BioscienceINDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT02979366 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 38 | Institut de Recherches Internationales ServierOTHER | 4 | May 18, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT03563560 | A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia(AML) | completed | Phase 1 | 10 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03787498 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 22 | Opna Bio LLCINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 7 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT01411267 | AC220 for Children With Relapsed/Refractory ALL or AML | completed | Phase 1 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04888468 | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | completed | Phase 1 | 9 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01433965 | Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | completed | Phase 1 | 16 | University of California, DavisOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | completed | Phase 1 | 10 | Mehrdad Abedi, MDOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | completed | Phase 1 | 120 | Xencor, Inc.INDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04327037 | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | completed | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03441555 | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 36 | AbbVieINDUSTRY | 3 | Feb 1, 2022 | clinicaltrials |
| NCT01578954 | Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction | completed | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02914977 | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | completed | Phase 1 | 18 | Tara LinOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT02083250 | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | completed | Phase 1 | 12 | Justin Watts, MDOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05149339 | Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia | completed | Phase 1 / Phase 2 | 38 | Zagazig UniversityOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03144245 | Study of AMV564 in Patients With AML | completed | Phase 1 | 53 | Amphivena Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02808442 | Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia(PALL) | completed | Phase 1 | 13 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 8, 2021 | clinicaltrials |
| NCT02464657 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT02328755 | Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT02746952 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia(CALM) | completed | Phase 1 | 25 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 1, 2021 | clinicaltrials |
| NCT02374333 | Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | completed | Phase 1 | 81 | University of PennsylvaniaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03625505 | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 61 | AbbVieINDUSTRY | 1 | Sep 14, 2021 | clinicaltrials |
| NCT03669172 | Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia | completed | Phase 1 / Phase 2 | 6 | Martín, José Luis Díez, M.D.INDIV | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01020539 | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia(AML/MDS/JMML) | completed | Phase 1 | 18 | Columbia UniversityOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT01221857 | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 12 | Gamida Cell ltdINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04194086 | Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia | completed | Phase 1 / Phase 2 | 42 | Zhujiang HospitalOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | completed | Phase 1 | 21 | Jazz PharmaceuticalsINDUSTRY | 2 | Jul 22, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2022source: clinicaltrials